Text Size

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: A meta-analysis of two phase IIIb clinical trials

Uusitalo H., Egorov E., Kaarniranta K., Astakhov Y., Ropo A.


  • 2016
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; Department of Ophthalmology, The Russian National Research Medical University, Moscow, Russian Federation; Department of Ophthalmology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russian Federation; Global Medical Affairs, Santen Oy, Tampere, Finland

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.


A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.


Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022